|
Treatment
|
Dosing Regimen
|
Strength (mg)
|
No. of Vials/Tablets
|
Ex-Factory Price
|
Source
|
| Lorlatinib |
100 mg/day |
100 |
30 |
€5757 |
Drug price bulletin, Greek Ministry of Health[@106172] |
| Pemetrexed |
500 mg /m2 every 3 weeks |
500 |
1 |
€545 |
| 100 |
1 |
€108 |
| Carboplatin |
750 mg every 3 weeks |
150 |
1 |
€17.23 |
| 450 |
1 |
€48.79 |
| Cisplatin |
75 mg /m2 every 3 weeks |
10 |
1 |
€4.14 |
| 50 |
1 |
€12.59 |
| 100 |
1 |
€24.89 |
|
Administration Costs per Cycle
|
Unit Cost
|
Source
|
| Lorlatinib |
€0 |
|
| P-ChT |
€112.20 |
Government gazette (Law 2150/27-9-2011) and drug price bulletin (Greek Ministry of Health)[@106172] |
|
Monitoring cost per cycle
|
€57.69 |
EOPYY website[@106174] and government gazette (Law, B′1181/8, May 2014) |
|
Post-progression Costs
|
Unit Cost
|
|
| Monitoring cost per cycle |
€57.69 |
EOPYY website[@106174] and government gazette (Law, B′1181/8, May 2014) |
| Subsequent treatment cost per patient |
€245.49 |
Drug price bulletin, Greek Ministry of Health[@106172] |
| End-of-life care cost per patient |
€7665 |
Kokkotou et al[@106176] |